Using oxytocin to reduce blood loss during cesarean hysterectomy for placenta accreta spectrum
Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With Placenta Accrete Spectrum Disorders Undergoing Cesarean Hysterectomy
This study tests if giving oxytocin during a cesarean hysterectomy can help reduce blood loss for women with placenta accreta spectrum.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 20 Years to 40 Years |
| Sex | Female |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06493968 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of oxytocin in minimizing intraoperative blood loss in patients diagnosed with placenta accreta spectrum (PAS) who are scheduled for cesarean hysterectomy. Participants will be randomly assigned to receive either oxytocin or a placebo during the procedure. The study aims to determine if the administration of oxytocin can lead to better outcomes in terms of blood loss compared to standard care. The trial will include patients with specific ultrasound markers indicative of PAS and will monitor their preoperative hemoglobin levels.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women with a singleton living fetus, a history of cesarean sections, and diagnosed with placenta accreta spectrum.
Not a fit: Patients with maternal medical disorders, known hypersensitivity to oxytocin, or those requiring emergency termination will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce intraoperative blood loss, improving safety and outcomes for patients undergoing cesarean hysterectomy due to PAS.
How similar studies have performed: While there is limited data on the specific use of oxytocin for this purpose, similar studies have shown promise in using uterotonics to manage blood loss in surgical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnancy of singleton living fetus * Previous one or more cesarean sections * Gestational age: \> 32 weeks * The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity". * Preoperative hemoglobin more than 10 gm/dl * Cases with PAS that will undergoing CS Hysterectomy Exclusion Criteria: * Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.…. * Any known or reported hypersensitivity to the used medication. * All cases with spontaneous placental separation at laparotomy. * All patients undergoing conservative management of PAS. * All cases which necessitate emergency termination.
Where this trial is running
Cairo
- Cairo University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Abdalla Mousa
- Email: Dr_abdallamousa@yahoo.com
- Phone: +201277664430
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.